Archive for the ‘Genetic Testing’ Category

LOS ANGELES, July 7, 2020 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) has collaborated with a consortium of 41 leading patient advocacy organizations, professional societies and industry partners to publish a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community. Use of consistent language will significantly improve patient awareness and understanding of potentially life-saving testing options available for both new cancer diagnoses and progression or recurrence of disease. In prostate cancer, testing is a crucial tool that may reveal additional treatment options and/or information for a man's family about their own cancer risk.

Research shows that despite widespread acceptance of the importance of testing, actual testing rates lag far behind best-practice recommendations for both biomarker testing for somatic (acquired) mutations and other biomarkers, and for germline genetic testing for identifying germline (inherited) mutations (also known as variants). Analysis by The Consistent Testing Terminology Working Group (Working Group) indicates that language disparity is a primary obstacle to patient communication with providers about testing for their specific cancer type. Further, development of consistent language can increase patient understanding and communication, facilitate shared decision making, support value-based care and assure concordance in policy development.

"Both types of testing biomarker testing and genetic testing for inherited cancer risk are important in the care of prostate cancer patients," said Dr. Andrea Miyahira, Director of Global Research and Scientific Communications at PCF. "One example is the very recent approval of medications for men with advanced prostate cancer and certain mutations in their tumor or inherited mutations that would be revealed through testing. Therefore, clear terminology and understanding between patients and providers is all the more vital. PCF supports this valuable collaboration across cancer types."

The Working Group is a consortium of 20 cancer patient advocacy groups representing solid tumor and hematologic malignancies, three professional societies, and 18 pharmaceutical and diagnostic companies and testing laboratories. Over the course of many years, multiple activities, led by numerous individual patient advocacy organizations and professional societies have developed the groundwork for this effort. The Working Group has launched a multi-faceted dissemination and communications effort to ensure that its recommendations and supporting materials are widely available among all key stakeholders within the cancer ecosystem, including providers, patient advocacy organizations, guidelines agencies, payers, and policymakers.

In developing its recommendations, the Working Group, first convened in 2019 by LUNGevity Foundation, identified 33 terms related to biomarker, genetic and genomic testing that were being used in patient education and clinical care within the different cancer communities. In many cases, multiple terms were used to describe the same test. Various testing modalities, the source of testing samples, and the multiplicity of gene mutations currently identifiable by testing, were contributing factors in this often-confusing overlap.

In the final analysis, three umbrella descriptor terms emerged as recommendations from the Working Group's milestone exploration: "Biomarker testing" was selected as the preferred term for tests that identify characteristics, targetable findings or other test results originating from malignant tissue and blood; "genetic testing for an inherited mutation" and "genetic testing for inherited cancer risk" were selected as consensus terms for tests used to identify germline (inherited) mutations.

"Far too many patients across all cancer types are still missing out on essential tests for biomarkers and inherited mutations indicating cancer risk," said Michelle Shiller, DO, AP/CP, MGP, Co-Medical Director of Genetics at Baylor Sammons Cancer Center and Staff Pathologist at Baylor University Medical Center. "With rates of biomarker testing and genetic testing for an inherited mutation at sub-optimal levels for numerous patient populations, patients are not benefiting from biomarker-directed care or not learning about their inherited cancer risk. Confusion around testing terms is a driving factor in this undertesting and ultimately has a detrimental impact on patient care."

"When someone is diagnosed with cancer, they're swept into a whirlwind of bewildering words and complex, pressing decisions. Our Working Group's goal is to help calm that storm of confusion with clear and consistent language that facilitates communication and medical decision-making. A unified voice and message from providers, industry and the patient advocacy community about testing is absolutely vital to optimal cancer care," said Nikki Martin, Director of Precision Medicine Initiatives at LUNGevity Foundation.

An abstract on the Working Group's recommendations was published in May 2020 as part of the American Society of Clinical Oncology (ASCO) Annual Meeting Virtual Library. The White Paper can be viewed in its entirety athttp://www.commoncancertestingterms.org/.

About LUNGevity Foundation LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the diseasewhile promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivorsand those who help them live better and longer lives.

Comprehensive resources include a medically vetted and patient-centric website, a toll-free HELPLine for support, the International Lung Cancer Survivorship Conference, and an easy-to-use Clinical Trial Finder, among other tools. All of these programs are to achieve our visiona world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization. Please visit http://www.LUNGevity.org to learn more.

About the Prostate Cancer Foundation The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has raised more than $830 million in support of cutting-edge research by more than 2,200 research projects at 220 leading cancer centers in 22 countries around the world. Thanks in part to PCF's commitment to ending death and suffering from prostate cancer, the death rate is down more than 50% and countless more men are alive today as a result. PCF research now impacts more than 73 forms of human cancer by focusing on immunotherapy, the microbiome, and food as medicine. For more information, visit PCF.org.

Media Contact: Donald Wilson Prostate Cancer Foundation (310) 428-4730 press@pcf.org

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-prostate-cancer-foundation-collaboration-with-pan-cancer-consortium-clarifies-and-promotes-consistent-use-of-common-terms-for-biomarker-and-germline-genetic-testing-301088974.html

SOURCE Prostate Cancer Foundation

Read the original post:
The Prostate Cancer Foundation Collaboration With Pan-Cancer Consortium Clarifies And Promotes Consistent Use Of Common Terms For Biomarker And...

SALT LAKE CITY, July 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene to provide genetic and financial assistance information to prospective patients. Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer. Gene interfaces with Myriad’s market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

We are excited to offer this innovative new tool for physicians and patients to provide best-in-class pre-test education solutions that we can supplement with live sessions when necessary,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. Myriad is highly focused on making the screening and testing process as streamlined as possible for healthcare providers and the implementation of this new technology will give their patients access to unparalleled online genetic education and support tools. This is especially important in the current environment with COVID-19 where patients may not be returning to the clinic setting and pre-test education can be particularly helpful as they work remotely with the healthcare provider to determine if testing is right for them.”

Gene will interactively engage individuals online, providing them with education about hereditary cancer prior to taking an online assessment to determine if they may be a candidate for genetic testing. For those who complete the preliminary assessment and meet criteria for further evaluation, Gene will automate a pre-test process that sends an educational link that displays interactive multimedia content and gives the option to start a live conversation with a patient educator, who is a certified genetic counselor. Gene can also assist in finding a healthcare provider who can help a patient make an informed, definitive decision whether testing is appropriate and then order testing if so. Myriad plans on launching the Gene chatbot for its Foresight® and Prequel prenatal tests and for companion diagnostic testing in oncology later this calendar year.

About OptraHEALTH: OptraHEALTH is focused on improving outcomes for consumers and leading Life Sciences and Healthcare organizations by utilizing a next-generation Artificial Intelligence Platform. OptraHEALTH’s flagship product GeneFAX is an AI-powered knowledge platform for genetic health and is available as a web plugin or mobile application.

About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, Prolaris and riskScore are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to implementation of this new technology giving patients access to unparalleled online genetic education and support tools; plans to launch the Gene chatbot for its ForeSight® and Prequel prenatal tests and for hereditary cancer testing in oncology later this calendar year; details of the functionality of the Gene chatbot; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Excerpt from:
Myriad Announces Partnership with OptraHEALTH to Deliver "Gene(TM)" a New AI Based Information Tool for Hereditary Cancer Patients |...

The Global Preimplantation Genetic Testing Market is the increasing awareness about preimplantation genetic testing among people suffering from genetic disorders is expected to drive demand for preimplantation genetic testing procedures.

The growth of this market is majorly driven by the rising rate of infertility across the globe, increasing number of fertility clinics worldwide, public-private investments in the field of preimplantation genetic testing, technological advancements in the field of genetic analysis, and the high risk of chromosomal abnormalities in the fetus with increasing maternal age.

Get Sample copy @https://www.orianresearch.com/request-sample/731193

Factors, such the high costs incurred in the PGD technologies hamper the growth of the market.

Growth initiatives by key market players and growing medical tourism in the forecast period will offer lucrative opportunities in the market.

Based on procedure type the market is segmented into Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis. The genetic screening segment accounted for the largest share due to continuous decline in female fertility (due to rising maternal age) and benefits offered by PGS, such as increased chances of healthy pregnancy across all age groups.

Based on end user, the Preimplantation Genetic Testing market is segmented into Maternity Centers & Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers.

Regionally, North America accounted for the largest share of the global preimplantation genetic testing market in 2016, followed by Europe. The large share in the North American region is mainly attributed to the rising number of IVF procedures.

Some of the key players operating in this market includeIllumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China)

Key Benefits of the Report:

* Global, Regional, Country, Procedure type, and End-User of Molecule Market Size and Forecast from 2014-2025

* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies

* Identification of key companies that can influence this market on a global and regional scale

* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies

* Detailed insights on emerging regions, Procedure type & End-user of molecule, and competitive landscape with qualitative and quantitative information and facts.

Global Preimplantation Genetic Testing Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share questions if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/731193

Target Audience:

* Preimplantation Genetic Testing providers

* Traders, Importer and Exporter

* Raw material suppliers and distributors

* Research and consulting firms

* Government and research organizations

* Associations and industry bodies.

Research Methodology: The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity Production, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:

* Original Equipment Manufacturer,

* Component Supplier,

* Distributors,

* Government Body & Associations, and

* Research Institute.

Order a Copy of this Report @https://www.orianresearch.com/checkout/731193

Table Of Content

1 Executive Summary

2 Methodology And Market Scope

3 Preimplantation Genetic Testing Market Industry Outlook

4 Preimplantation Genetic Testing Market Type Outlook

5 Preimplantation Genetic Testing Market Application Outlook

6 Preimplantation Genetic Testing Market Regional Outlook

7 Competitive Landscape

End Of The Report

Disclaimer

Customization Service of the Report:Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

See more here:
Impact of COVID-19 on PREIMPLANTATION GENETIC TESTING MARKET: 2020 GLOBAL INDUSTRY SIZE, SEGMENTS, REGIONAL OUTLOOK, DEVELOPMENT STATUS, KEY PLAYERS...

MarketsandResearch.biz adds a new report titled Global Direct-to-Consumer Genetic Testing (DTC-GT) Market 2020 by Company, Regions, Type and Application, Forecast to 2026 to its online database. The report offers a detailed overview of the factors, the latest market insights with upcoming trends, and breakdown of the products and services. The report presents information on industry trends, top manufacturers, product, material and application, and manufacturers. The study provides key statistics on the market status, size, share, growth factors of the global Direct-to-Consumer Genetic Testing (DTC-GT) market. The report is formulated with respect to the regional landscape of the market incorporating extensive details about the types and application spectrums of this business space. The document covers the emerging players data, including competitive situation, sales, revenue, and global market share.

Market Outline:

The report analyzes the global Direct-to-Consumer Genetic Testing (DTC-GT) market size and share of each separate segment in the market. Substantial information about the company revenue, production, price, as well as gross margins has been provided. In addition, it delivers details regarding the basic information of every prominent rival in the business, manufacturing base, and the business overview, as well as SWOT examination, sales, value, capacity, regional market examination, and market forecast for 2020 to 2026 time-period. The key geographical regions are analyzed in terms of the parameters such as production, market share in terms of the manufacturers as well as with regards to application and type. A detailed analysis of the market drivers and the emerging regional markets has also been segmented separately in the report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/54613

Based on the product types, market types split into: Over-the-Counter (OTC) Channel, Online Channel

By application, the market is split into: Ancestry-based Genetic Tests, Health and Wellness-based Genetic Tests, Entertainment-based Genetic Tests,

Our best analysts have surveyed the market report with the reference of inventories and data given by the key players: Family Tree DNA, MyHeritage, EasyDNA, Ancestry.com LLC, 24Genetics, Dante Labs, Atlas Biomed, Genebase, Mapmygenome,

Market size segmentation by region & countries: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Executive Outline: This section comprises the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers. It discusses gross margin, sales, revenue, production, market share, CAGR, and market size by region. The report offers a complete forecast of the global Direct-to-Consumer Genetic Testing (DTC-GT) Market by product, application, and region.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/54613/global-direct-to-consumer-genetic-testing-dtc-gt-market-2020-by-company-regions-type-and-application-forecast-to-2026

What Benefits Does This Report Provide?

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Read the original post:
Global Direct-to-Consumer Genetic Testing (DTC-GT) Market 2020 by Company, Regions, Type and Application, Forecast to 2026 - Jewish Life News

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Direct-Access Genetic Testing Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Direct-Access Genetic Testing market.

The research study includes the latest updates about the COVID-19 impact on the Direct-Access Genetic Testing sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Direct-Access Genetic Testing manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=174200&utm_source=3WN&utm_medium=888

The Direct-Access Genetic Testing market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Direct-Access Genetic Testing market.

This study analyzes the growth of Direct-Access Genetic Testing based on the present, past and futuristic data and will render complete information about the Direct-Access Genetic Testing industry to the market-leading industry players that will guide the direction of the Direct-Access Genetic Testing market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Direct-Access Genetic Testing market. Additionally, it includes a share of each segment of the Direct-Access Genetic Testing market, giving methodical information about types and applications of the market.

Reasons for Buying Direct-Access Genetic Testing Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Direct-Access Genetic Testing market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=174200&utm_source=3WN&utm_medium=888

In the end, the Direct-Access Genetic Testing market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Direct-Access Genetic Testing market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Iris Recognition Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Offshore AUV and ROV Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Oil & Gas Analytics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Produced Water Treatment Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Underwater Monitoring System for Oil and Gas Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Go here to read the rest:
Direct-Access Genetic Testing Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

Hereditary cancer testing is a process of identifying an inherited gene mutation that increases the risk of cancer development. It mainly includes predictive genetic testing and clinical DNA sequencing, in predictive genetic testing, patients family history is analyzed for any inherited mutation from ancestry. In DNA sequencing, entire DNA or genome of an individual is analyzed. It is useful for testing many genetic mutations at a time. Here are few hereditary cancers namely: bowel cancer, breast cancer, kidney cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, thyroid cancer, womb cancer and others. The basic hereditary cancer testing is similar to other cancers and it mainly includes lab tests, imaging procedures, and biopsy. Lab test mainly includes analysis of blood, urine and other body fluids for identification of abnormal cell growth. Imaging procedures like CT scan, nuclear scan, ultrasound, MRI, PET scan, and x-rays are used to identify tumor growth in the body. A biopsy is used to diagnosis of cancer and biopsy can be done with either the needle, endoscope or surgery. The cancer testing mainly depends on patient population and severity of hereditary cancer.

To remain ahead of your competitors, request for a sample here@ https://www.persistencemarketresearch.com/samples/18964

Hereditary Cancer Testing Market: Drivers and Restraints

Rising prevalence of hereditary cancer due to mutations in the genes is one factor which influencing early detection of hereditary cancer. So, it is the prime requisite for early detection of hereditary cancer which drives the robust growth of the hereditary cancer testing market. The severity is also very high when compared to other cancers if hereditary cancer is left undiagnosed in the early stages and it increases the risk of mortality. DNA sequencing is a cost-effective and more efficient than traditional methods. Because in DNA sequencing multiple gene-panels is used to test many inherited mutations at a time. But in the traditional method, at a time only one gene mutation can be analyzed and it increases error and time for testing. So, increasing demand for rapid diagnostics for early detection of hereditary cancer testing acts as a driver in the burgeoning growth of the hereditary cancer testing market.

Due to difficulties in accessing the complete genomic data for early detection and prevention acts as a restraint in the growth of the hereditary cancer testing market

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/18964

Hereditary cancer testing Market: Segmentation

Segmentation based on Diagnosis Type

Segmentation based on End Users

Hereditary Cancer Testing Market: Market Overview

Global Hereditary cancer testing market witnessed rapid growth due to rising demand for non-invasive techniques for detection of hereditary cancer. Even though the demand increasing for non-invasive techniques, histopathological detection acts as a golden standard for diagnosis of hereditary cancer. The manufacturers of hereditary cancer diagnostics are mainly concentrated on technological advancements to increase the reliability of the tests. Increasing government funding for improvement of rapid diagnostics and rising concerns of hereditary cancer are driving the growth of the hereditary cancer testing market. The future of hereditary cancer testing market is anticipated to grow at double CAGR during the forecast period.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/18964

Hereditary Cancer Testing Market: Region-wise Overview

Global hereditary cancer testing market segmented into North America, Europe, Asia -Pacific & Japan, The Middle East and Africa regions and Latin America by region wise. North America dominates the global hereditary cancer testing Market due to the high prevalence among the patient population, and in North America, USA is a major stakeholder due to the presence of strong players. Europe and Asia-Pacific are the fastest growing market in hereditary cancer testing market due to the rising awareness. Economic conditions in the Asia-Pacific drives the global hereditary cancer testing market to new heights. The Latin America and the Middle East and Africa region also showed significant growth due to growing healthcare concerns and changing government policies in these regions.

Hereditary cancer testing Market

The end users are major players like hospitals, clinics, and diagnostic centers are the major stakeholders in the global hereditary cancer testing market. The companies are mainly focusing on intense marketing to convey health benefits of hereditary cancer testing market.

See the rest here:
Hereditary Cancer Testing Market to Witness Surge in Demand Owing to Rising End-use Adoption - Lake Shore Gazette

This market research report includes a detailed segmentation of theglobal molecular diagnostics marketby application (oncology, blood testing, infectious disease, genetic testing, and tissue typing), by technology type (PCR, INAAT, Microarray, Hybridization, DNA Sequencing and other MDX technology), by end-users (hospitals, reference laboratories and others), and by regions (Americas, APAC, EMEA, and RoW). The market research report identifies F.Hoffmann-La Roche, Abbott Diagnostics, Siemens Healthineers, Danaher, and Hologic as the major vendors operating in the global molecular diagnostics market.

Request For Report[emailprotected]https://www.trendsmarketresearch.com/report/sample/10454

Overview of the Global Molecular Diagnostics Market Research

Infoholicsmarket research report predicts that the globalmolecular diagnostics market will grow at a CAGR of 8.7% during the forecast period.The market for molecular diagnostics is driven by increasing prevalence of infectious and other lifestyle diseases, increasing demand for non-invasive biomarker-based tests, growing adoption of point-of-care testing, and high growth of the market in emerging countries. Increasing number of mergers & acquisitions and growing significance of companion diagnostics are providing opportunities for the market growth. Low awareness about standardization, stringent regulatory approval process, and lack of skilled labors are hampering the market growth.

According to the molecular diagnostics industry analysis, North America accounted for the largest share of the global molecular diagnostics market in 2017. The reason for the markets growth in the Americas is the increasing incidences of disease and organ transplantation in the US along with increasing funding by government and private players and increased adoption of personalized medicine in clinical practices are some of the factors driving the molecular diagnostics market growth. The Asia Pacific region is expected to witness the fastest growth rate due to the large patient pool, increasing awareness, and rising healthcare expenditure.

Molecular Diagnostics Market Research competitive analysis and key vendorsMolecular diagnostics are performed mainly to examine the existence of the disease in blood, tissue, or even in bones. The importance of nucleic acids and other cellular biomarkers in defining the vital cellular process has facilitated medical advancements in the diagnosis of various diseases. Early diagnosis of the disease is one of the key advantages of this technology.The capacity of molecular diagnostics to systematize molecular reactions for the enhancement of the clinical diagnosis has put healthcare in the front line. The increasing importance of molecular diagnostic tests has resulted in the launch of new tests and also increased acquisition, strategic partnership, and funding to develop new tests and technologies. For instance, in April 2018, NanoString Technologies, Inc. launched a Breast Cancer 360 (BC 360) research panel. In July 2017, MDxHealth SA announced the commercial launch of its AssureMDx for bladder cancer test in the US as a laboratory developed test. Illumina recently started a new company, named GRAIL, for liquid biopsy. It invested $100 million and raised another $900 million through public funding to develop new non-invasive tests for cancer diagnosis.

Get Complete TOC with Tables and[emailprotected]https://www.trendsmarketresearch.com/report/discount/10454

Some of the Key Vendors in the Molecular Diagnostics Market Research are:

Molecular Diagnostics Market Research by Application type

In 2017, the infectious disease application occupied the largest share due to large number of patients suffering from hospital-associated infection, sexually transmitted infection (STI), hepatitis, respiratory infection, pathogen ID detection, and others is fostering the market growth, but oncology is expected to grow at the highest growth rate during the forecast period due to increasing incidence of cancer globally.

Molecular Diagnostics Market Research By Technology

In 2017, the PCR segment occupied the largest share. PCR is a gold standard technique for DNA amplification and is the primary technique conducted prior to any molecular diagnostic examination Next-generation sequencing and microarray are expected to grow at the fastest rate during the forecast period.

Molecular Diagnostics Market Research By End-Users

In 2017, the hospitals occupied the largest share and is expected to continue the same trend during the forecast period.

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/10454

Molecular Diagnostics Market Research Benefits

The report provides detailed information about the usage and adoption of molecular diagnostics market in various applications and regions. With that, key stakeholders can find out the major trends, drivers, investments, vertical players initiatives, government initiatives toward the product adoption in the upcoming years, along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to have an impact on market growth. Additionally, the report gives complete details about the business opportunities to key stakeholders to expand their business and capture revenues in the specific verticals. The report will help companies interested or established in this market to analyze the various aspects of this domain before investing or expanding their business in the molecular diagnostics market.

Read the original here:
Worldwide Molecular Diagnostics Market Market to Witness over XX% Growth 'in Revenue During the COVID-19 Pandemic 2023 3w Market News Reports - 3rd...

This years Yukon River Chinook salmon run isnt as disastrous as originally feared but is still tracking, to date, as the smallest since 2013.

The story for summer chum, however, appears to be much grimmer.

Fred West, a fisheries biologist with the Alaska Department of Fish and Game, said at a weekly in-season salmon teleconference June 30 that projections of the run had improved with good passage at the Pilot Station sonar, located near the mouth of the river.

West said 98,851 fish had been counted by that point, a vast improvement from a week before although still short of the historical average of 131,000.

At the time of the last teleconference, less than 35,000 fish had made it through at whats typically the halfway point of the run.

An international agreement aims to get between 42,500 to 55,000 Canadian-origin Chinook to their spawning grounds in order to preserve the species.

West said that genetic testing done on the first pulse of fish throughout June indicated that 62 per cent of the fish sampled were Canadian origin, which was higher than officials had expected. The first pulse, at that point, was estimated to have reached Grayling, Alaska, which is about a fifth of the way to the Canadian border.

According to data on the departments website, 117,597 Chinook had been counted entering the Yukon River as of July 2. Thats the lowest number to date since 2013, when only 102,116 Chinook had been counted at Pilot.

West said June 30 that crews were expecting to have the sonar project at Eagle, Alaska, which is near the border with the Yukon, set up by July 1.

Alaskan community representatives on the teleconference mostly reported poor fishing conditions, with high water levels and a large amount of debris in the water. Some said that fishermen were starting to get frustrated about catch restrictions and feared that, even with chum harvest, they wouldnt be able to catch enough fish this season to feed their families.

The Yukon River summer chum are seeing extremely low numbers so far; 304,500 were counted at Pilot, West said during his update, compared to the historical average of one million to date.

No Chinook have crossed into Canadian waters to date, with the run appearing to track much later than usual.

Jesse Trerice, the Yukon fishery manager for Fisheries and Oceans Canada, said during the June 30 teleconference that Canada was finalizing its management plan and was encouraged to hear about better numbers coming out of Pilot.

Contact Jackie Hong at jackie.hong@yukon-news.com

Salmon

See the original post:
Yukon River Chinook run not as disastrous as feared, but still small - Yukon News

The Jacksonville Sheriffs Office says one of its former detectives and his then-wife have been arrested in connection into a 1999 murder.

Undersheriff Pat Ivey says the case involved the May 17, 1999, stabbing of 39-year-old Saad Kawaf in the Deerwood/Baymeadows area.

To give a basic rundown of the incident is, the victim along with his wife, in those morning hours were approached by a white male and white female suspect, in which the victim was stabbed multiple times and succumbed to his injuries. The female victim was tied up and approximately $30,000 in funds, cash, was stolen, explains Ivey.

At the time, Ivey said the only information on the suspects was that they were a white man and a white woman.

In 2003, Ivey says two DNA profiles were developed. Then in May 2020, he says further genetic testing led to the development of profiles that gave indications of who the suspects were.

Ultimately, in June 2020, Ivey says the FDLE was able to provide detectives with the names of the potential suspects.

It turns out that your suspect was indeed William Robert Baer Jr., white male, 64 years of age, who was a retired Jacksonville Sheriffs Office police officer and his then-wife, Melissa Shafer, white female, 50 years of age, says Ivey.

Ivey says Baer was arrested Wednesday night in Jacksonville, Florida, while Shafer was arrested in Jefferson City, Missouri, on Thursday afternoon.

Ivey says Baer was an active intelligence unit detective with JSO at the time of the murder and that his initial contact with Kawaf stemmed directly from his assignment with the sheriff's office.

Baer started with JSO in 1975 and retired in 2002, according to Ivey.

Were told that the two were arrested without incident.

The family of Kawaf released a statement to our partner Action News Jax following the arrests:

We are thrilled. We are grateful. Not a day has gone by that we dont miss our beloved Saad. The past 21 years have been the hardest to not only be without a man who meant so much to our family but to know that the people who did this were not held accountable for their actions. We are grateful to the brave members of the cold case unit and all members of law enforcement who have worked tirelessly on our behalf to ensure justice and that Saads memory will never be forgotten.

Heather Kayal - Victims Niece

Read more:
JSO: Former detective, then-wife arrested in 1999 fatal stabbing in Deerwood area - WOKV

Florida has enacted House Bill 1189, which prohibits life and long-term care insurers from canceling, limiting, or denying coverage or adjusting premium rates based on genetic information.

As we previously reported, the bill amends Florida Statute 627.4301, which currently prohibits health insurers use of genetic information for insurance purposes. As amended, the statute removes former carve-outs for life, disability, and long-term care insurers, but certain carve-outs remain, such as those for accident-only policies, hospital indemnity or fixed indemnity policies, dental policies, and vision policies. The amended statute further provides that, in the absence of a diagnosis of a condition related to genetic information, life and long-term care insurers may not cancel, limit, or deny coverage or establish differentials in premium rates, based on such information. Additionally, those insurers are prohibited from requiring or soliciting genetic information, using genetic test results, or considering a persons decisions or actions relating to genetic testing in any manner for any insurance purpose.

It is worth noting that prior to final passage, the bill was amended to include language instructing that it should not be construed as to prevent a life or long-term care insurer from accessing an individuals medical record as part of an application exam or from considering a medical diagnosis included in an individuals medical record, even if a diagnosis was made based on the results of a genetic test. Nonetheless, the amended statute will likely prevent life insurers and long-term care insurers from asking about or obtaining the results from direct-to-consumer genetic tests.

See the original post here:
Florida Bill Restricting Life Insurers' Use of Genetic Information Signed by Governor DeSantis - Lexology

It is our aim to provide our readers with report for Direct-to-Consumer Genetic Testing (DTC-GT) Market, which examines the industry during the period 2020 2026. One goal is to present deeper insight into this line of business in this document. The first part of the report focuses on providing the industry definition for the product or service under focus in the Direct-to-Consumer Genetic Testing (DTC-GT) Market report. Next, the document will study the factors responsible for hindering and enhancing growth in the industry. After covering various areas of interest in the industry, the report aims to provide how the Direct-to-Consumer Genetic Testing (DTC-GT) Market will grow during the forecast period.

The major vendors covered:

Family Tree DNA, MyHeritage, EasyDNA, Ancestry.com LLC, 24Genetics, Dante Labs, Atlas Biomed, Genebase, Mapmygenome and more

The final report will add the analysis of the Impact of Covid-19 on Direct-to-Consumer Genetic Testing (DTC-GT) Market.

Request a free sample copy @ https://www.reportsandmarkets.com/sample-request/direct-to-consumer-genetic-testing-dtc-gt-global-market-status-and-trend-report-2013-2023?utm_source=jewishlifenews&utm_medium=38

The Direct-to-Consumer Genetic Testing (DTC-GT) Market report between the years 2020 2026 will highlight the current value of the industry. At the same time, there is also an estimate of how much this line of business will be worth at the end of the forecast period. As it is our goal to maintain high levels of accuracy at all times, we will take a look at the CAGR of the Direct-to-Consumer Genetic Testing (DTC-GT) Market. We make sure that all the information available in this report has excellent levels of readability. One way we achieve this target is by Direct-to-Consumer Genetic Testing (DTC-GT) Market segmentation. Going through the report for 2020 2026 will bring our readers up-to-date regarding this industry.

While examining the information from this document, one thing becomes clear, the elements which contribute to increase in demand for the product or service. At the same time, there will be a focus on what drives the popularity of these types of products or services. This report is for those who want to learn about Direct-to-Consumer Genetic Testing (DTC-GT) Market, along with its forecast for 2020 2026. Information regarding market revenue, competitive partners, and key players will also be available.

Segmentation

As discussed earlier, there is segmentation in the Direct-to-Consumer Genetic Testing (DTC-GT) Market report, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Direct-to-Consumer Genetic Testing (DTC-GT) Market. At the same time, there is emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Direct-to-Consumer Genetic Testing (DTC-GT) Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of the Direct-to-Consumer Genetic Testing (DTC-GT) Market report, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows Middle East and Africa, South and North America, Europe, and Asia Pacific. From the Direct-to-Consumer Genetic Testing (DTC-GT) Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From this Direct-to-Consumer Genetic Testing (DTC-GT) Market report, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Direct-to-Consumer Genetic Testing (DTC-GT) Market report.

If you have any special requirements about this Direct-to-Consumer Genetic Testing (DTC-GT) Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/direct-to-consumer-genetic-testing-dtc-gt-global-market-status-and-trend-report-2013-2023?utm_source=jewishlifenews&utm_medium=38

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Originally posted here:
Impact of COVID-19 on Direct-to-Consumer Genetic Testing (DTC-GT) 2020 by Industry Analysis, Growth Opportunity, Future and Forecast to 2026 - Jewish...

The global Predictive Genetic Testing market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Predictive Genetic Testing market player in a comprehensive way. Further, the Predictive Genetic Testing market report emphasizes the adoption pattern of the Predictive Genetic Testing across various industries.

The Predictive Genetic Testing market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/31204

key players in the predictive genetic testing market. The significant competitive strength of the existing players in the evolving landscape of the global predictive genetic testing market is anticipated to offer new prospect in widening the application of the predictive genetic testing, substantially driving predictive genetic testing market growth. The key manufacturers of the predictive genetic testing are greatly concentrated on the technical edification of the end users to improve consumer outcomes. Furthermore, the adoptions of advanced predictive genetic testing services is expected to create lucrative growth opportunities for the service and third-party market competitors. Growing inclination toward trend in predict is prevention is estimated to offer growth opportunity for Predictive genetic testing market. Selection of treatment regimen with Predictive genetic testing is projected to aid capturing higher share in Predictive genetic testing market.

Geographically, global Predictive genetic testing market is segmented into seven key regions viz. North America, Latin America, Europe, South Asia, East Asia Oceania and Middle East & Africa. North America is prominent region in Predictive genetic testing Market. Advancement in genetic care facilities, higher adoption to lifestyle changes, increase awareness about genetic disease, increase in preventative care and favorable government policies have improved the regulatory scenario for predictive genetic testing devices in north America. Additionally in Asia pacific region considerably higher market growth rate is expected due to constantly rising population and higher incidence of genetic abnormality. Relatively affecting the Predictive genetic testing market.

Some of the major key players competing in the global Predictive genetic testing Market are Myriad Genetics, Inc., Abbott Laboratories, Illumina, Inc., Genesis GeneticsThermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., , Agilent Technologies, F. Hoffmann-La Roche Ltd., Counsyl, Inc., ARUP Laboratories. BGI among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Buy the report at a discounted rate!!! Exclusive offer!!!

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/31204

The Predictive Genetic Testing market report offers a plethora of insights which include:

The Predictive Genetic Testing market report answers important questions which include:

The Predictive Genetic Testing market report considers the following years to predict the market growth:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/31204

Why Choose Predictive Genetic Testing Market Report?

Predictive Genetic Testing Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

See the article here:
Predictive Genetic Testing Market Report 2019: With Essential Analysis of Market, Industry News and Policies by Regions, Top Manufacturers, Types and...

Genetic Testing Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Genetic Testing Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/307245

GeneDx, Invitae, Pathway Genomics, Counsyl Inc, Asper Biotech, GenePlanet, Courtagen Life Sciences, Gene By Gene, Natera Inc, Regulatory, GeneTests, United Gene, HI Gene, Berry Genomics, 23andMe Inc, 360Jiyin, Novogene, CapitalBio, Agen, Biomedlab, Biomarker, Annoroad, Aiyin Gene, Aijiyin, Repconex, Find Bio-Tech, SinoGenoMax, Gene Kang, Geeppine, BGI of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Genetic Testing industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Genetic Testing market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Genetic Testing market for your business? It brings to light the consumption in the Genetic Testing industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Genetic Testing market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Genetic Testing industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Genetic Testing industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Genetic Testing Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

View original post here:
COVID-19 Impact on Genetic Testing Market Down to a Trickle Month Other Traders Cling on the Hope: GeneDx, Invitae, Pathway Genomics - Daily Research...

Predictive Genetic Testing And Consumer/Wellness Genomics Marketreport focused on the comprehensive analysis of current and future prospects of the Predictive Genetic Testing And Consumer/Wellness Genomics industry. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. An in-depth analysis of past trends, future trends, demographics, technological advancements, and regulatory requirements for the Predictive Genetic Testing And Consumer/Wellness Genomics market has been done in order to calculate the growth rates for each segment and sub-segments.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report:

https://www.a2zmarketresearch.com/sample?reportId=115261

Top Key Vendors of this Market are:

Illumina, BGI, Genesis Genetics, Myriad Genetics, 23andMe, Inc, Color Genomics Inc, Pathway Genomics, ARUP Laboratories.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Predictive Genetic Testing And Consumer/Wellness Genomics market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Predictive Genetic Testing And Consumer/Wellness Genomics markets trajectory between forecast periods.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Predictive Genetic Testing And Consumer/Wellness Genomics market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Predictive Genetic Testing And Consumer/Wellness Genomics market.

Hurry Up! To Get Upto 25% on this Report:

https://www.a2zmarketresearch.com/discount?reportId=115261

The report summarized the high revenue that has been generated across locations like, North America, Japan, Europe, Asia, and India along with the facts and figures of Predictive Genetic Testing And Consumer/Wellness Genomics market. It focuses on the major points, which are necessary to make positive impacts on the market policies, international transactions, speculation, and supply demand in the global market.

Reasons for buying this report:

Table of Contents

Global Predictive Genetic Testing And Consumer/Wellness Genomics Market Research Report 2020 2026

Chapter 1 Predictive Genetic Testing And Consumer/Wellness Genomics Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Predictive Genetic Testing And Consumer/Wellness Genomics Market Forecast

For Direct Purchase, Visit @:

https://www.a2zmarketresearch.com/buy?reportId=115261

If you have any special requirements, please let us know and we will offer you the report as you want.

Visit link:
Predictive Genetic Testing And Consumer/Wellness Genomics Market to Witness Explosive Rise by 2026 with Top Key Players like Illumina, BGI, Genesis...

Newswise Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.

Inherited retinal degenerations (IRDs), such as retinitis pigmentosa, are a group of blinding eye diseases caused by mutations in over 270 different genes. Mutations in the PRPF31 gene are the second most common cause of dominant IRD and lead to defects in the function of the retinal pigment epithelial (RPE) cells and photoreceptors of the retina. Previous lab-based research performed by members of the Ocular Genomics Institute at Harvard Ophthalmology, led by Eric A. Pierce, MD, PhD, demonstrated that adeno-associated virus (AAV)-mediated gene augmentation therapy for PRPF31 can restore normal function to PRPF31 mutant RPE cells.

Biogen (Nasdaq: BIIB), a biopharmaceutical company that discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies, will build upon this prior work, and conduct the studies needed for clinical development of PRPF31 gene therapy. This includes the pre-clinical studies needed to support progression to clinical trials of PRPF31 gene therapy. As part of the agreement, Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all U.S. Food and Drug-Administration (FDA) required investigational new drug (IND) enabling studies, clinical development and commercialization.

The treatment of IRDs with highly effective AAV-based gene therapies is core to Biogens ophthalmology strategy, said Chris Henderson, Head of Research, Biogen. This agreement underscores our commitment to that strategy and builds off of our acquisition of Nightstar Therapeutics in 2019 and our active clinical trials of gene therapies for different genetic forms of IRD. We are excited to work with Massachusetts Eye and Ear and look forward to applying our preclinical and clinical experience to their leading PRPF31 program.

We are thrilled to work with Biogen, who will bring to this effort its deep experience with the clinical development process, as we work toward our goal of developing a gene therapy for people with PRPF31-related eye disease, added Dr. Pierce, who is the William F. Chatlos Professor of Ophthalmology at Harvard Medical School. My ultimate hope for patients with inherited retinal disorders due to mutations in PRPF31 is that a gene therapy will preserve and potentially restore some of their vision.

About the Ocular Genomics Institute

The Ocular Genomics Institute at Harvard Ophthalmology aims to translate genomic medicine into precision ophthalmic care for patients with inherited eye disorders. It is home to one of the leading centers for early-phase clinical trials of therapies for inherited retinal degenerations, with seven gene-based and one stem cell trial currently in progress. The group works in conjunction with other departments throughout Harvard Medical School and Mass. Eye and Ear, including the Bioinformatics Center and Grousbeck Gene Therapy Center.

Dr. Pierces lab, established in 2011, is dedicated to research in an effort to improve the understanding of the molecular bases of IRDs so that rational therapies can be developed for these diseases.

In 2018, Mass. Eye and Ear surgeons performed the first post-FDA approval gene therapy for patients with a form of inherited retinal blindness caused by mutations in the gene RPE65 by injecting an AAV-based drug treatment into a patients eye, which restored vision in a 13-year-old boy. This therapy, called Luxturna, is now being used to treat patients with RPE65-associated retinal degeneration around the world.

One of the exciting aspects of our collaboration with Biogen is that mutations in the PRPF31 gene affect approximately 10 to 20 times more people than mutations in the RPE65 gene, said Dr. Pierce. Success with PRPF31 gene therapy could provide visual benefit to more patients, which is our ultimate goal.

Mass. Eye and Ear was one of the first centers to offer life-changing gene therapies to patients with inherited retinal disease, and we are thrilled with this new opportunity to develop a translational retinal therapy that could help even more patients, said Joan W. Miller, MD, Chief of Ophthalmology at Mass. Eye and Ear, Massachusetts General Hospital, and Brigham and Womens Hospital, and Chair of Ophthalmology and the David Glendenning Cogan Professor of Ophthalmology at Harvard Medical School.

According to Chris Coburn, Chief Innovation Officer, Mass General Brigham, the collaboration with Biogen illustrates the importance of academia and industry teaming to solve problems for patients worldwide. We are eager to see this progress reach patients who are challenged by blinding, degenerative eye disease, said Coburn. We look forward to working with Biogen to advance this break-through innovation.

Patients with an inherited retinal disease require genetic testing prior to being considered for any gene therapy treatment.

About Massachusetts Eye and Ear

Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass. Eye and Ear specializes in ophthalmology (eye care) and otolaryngologyhead and neck surgery (ear, nose and throat care). Mass. Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass. Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 20192020 Best Hospitals Survey,U.S. News & World Reportranked Mass. Eye and Ear #4 in the nation for eye care and #2 for ear, nose and throat care.For more information about life-changing care and research at Mass. Eye and Ear, visit our blog,Focus, and follow us onInstagram,TwitterandFacebook.

About Harvard Medical School Department of Ophthalmology

The Harvard Medical SchoolDepartment of Ophthalmologyis one of the leading and largest academic departments of ophthalmology in the nation. Composed of nine affiliates (Massachusetts Eye and Ear, which is home to Schepens Eye Research Institute; Massachusetts General Hospital; Brigham and Womens Hospital; Boston Childrens Hospital; Beth Israel Deaconess Medical Center; Joslin Diabetes Center/Beetham Eye Institute; Veterans Affairs Boston Healthcare System; Veterans Affairs Maine Healthcare System; and Cambridge Health Alliance) and several international partners, the department draws upon the resources of a global team to pursue a singular goaleradicate blinding diseases so that all children born today will see throughout their lifetimes. Formally established in 1871, the department is committed to its three-fold mission of providing premier clinical care, conducting transformational research, and providing world-class training for tomorrows leaders in ophthalmology.

See more here:
Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise

The Esoteric Testing Market report upholds the future market predictions related to Esoteric Testing market size, revenue, production, Consumption, gross margin and other substantial factors. It also examines the role of the prominent Esoteric Testing market players involved in the industry including their corporate overview. While emphasizing the key driving factors for Esoteric Testing market, the report also offers a full study of the future trends and developments of the market.

In the report the esoteric testing market, the market is expected to reach US$ $ 45,081.6 Mn in 2025 from US$ 19,868.2 in 2017. The market is estimated to grow with a CAGR of 11.7% from 2018-2025.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/13610

The test type segment of the esoteric testing market includes infectious diseases testing, oncology testing, genetic testing, neurology testing, endocrinology testing, toxicology testing and others. The test type segment for the esoteric testing market was valued at US$ 19,868.2 Mn in 2017 and is estimated to reach US$ 45,081.6 Mn by 2025. The infectious diseases testing segments is likely to dominate the market in the coming future owing to large number of infectious disease tests that are performed in clinical laboratories, technological innovations in molecular diagnostics and increasing healthcare infrastructure in developing nations. The endocrinology testing segments are the fastest growing segment in the test type and is expected to be the fastest growing segment in the forecast period owing to the increase in the number of the endocrinology tests.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/13610

The esoteric testing market is driven by the driving factor such as rising prevalence of infectious diseases, growing awareness regarding early detection using specific diagnostics tests and increasing geriatric population & associated growth in chronic diseases. The market is likely to restrain its growth due to the factors such as lack of skilled professionals and poor reimbursement scenarios for the esoteric testing. Whereas the trend of utilizing the technologies in esoteric testing for various applications are likely to propel the growth of the market.

What will you get in this report?

The esoteric testing market as per the technology the segment is segmented as chemiluminescence immunoassay, real-time PCR, flow cytometry, mass spectrometry, enzyme-linked immunosorbent assay and others. The market of chemiluminescence immunoassay has the highest market share in 2017, contributing a market share of 25.2% and is expected to retain its dominance during the forecast period from 2018 to 2025. The higher acceptance of the chemiluminescence immunoassay for the esoteric testing are due to the advantages for the analytical procedures likely to propel the esoteric testing market in the coming future. Similarly, the enzyme-linked immunosorbent assay contributed 21.1% of the market share in the year 2017 and is expected to be the fastest growing market in the coming forecast period.

Some of the major primary and secondary sources included in the report esoteric testing market are International Diabetes Federation, Laboratory Corporation of America Holdings Diagnostics, Ministry of Health, South Africa Regional Global Disease Detection Centre, Centers for Disease Control and Prevention, National Department of Health, National Health Laboratory Service, Dubai Health Authority, Dubai Healthcare City, Joint Advisory Group, New Rural Cooperative Medical System and more.

Some of the Highlights about Table of Content of Esoteric Testing Market

1 Esoteric Testing Market overview

2 Executive Summary

3 Market Drivers, Challenges and Trends

4 Marketing, Distributors and Customer

5 Key Players Analysis

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/13610

See the article here:
Esoteric Testing Market Analysis, Competitive Strategies and Forecasts to 2025 - CueReport

Christine Stanley, Ph.D., Chief Director of Clinical Genomics at Variantyx

The answer to questions about human disease can be found in our genes. The difficulty in the past has been the testing process, a sort of trial and error approach of drilling down into the multitude of variants that can be found within the genes, variants that when analyzed in tandem with detailed clinical histories can actually tell the story and lead to a faster diagnosis.

Human beings carry around 20,000 genes and, of those, approximately 5,000 are somewhat understood, and those genes can be associated with several diseases and each disease can be associated with dozens of clinical symptoms or more. It was believed that five percent or less of the human population carry variants involved in genetic diseases. But a recent study in the Annals of Internal Medicine, now suggests the number of people with variants linked to genetic diseases is closer to 20 percent. Many other factors may determine whether an individual actually develops a disorder, but these numbers suggest the acceptance of a new approach that provides the most useful diagnostic data from a single test thats easier on the patients and families and provides the shortest time to a diagnosis and the best chance at implementing treatments.

Here is an important reason. Parents with children suspected of having a genetic disease routinely face a diagnostic odyssey that typically lasts five to seven years and entails seeing an average of seven different physicians. Its an odyssey that comes with an average cost of diagnosis reaching $21,099, more than seven times the cost of a single whole-genome sequencing test.

Historically, genetic testing has been really disjointed. Tests that were developed 10 to 15 years ago are still being run today by laboratories. These tests target extremely specific areas for an exceedingly small number of changes that cause a certain disease. It is like looking under a lamp post. And an individual, who is suspected of having the disease, will be tested for one particular variant or a small number of variants. It is an approach that is lacking in quick, definitive, and accurate results. Unless the tested area accounted for the majority of the disease-causing variants, it then forces the ordering of more tests to try to find other causes of the disease, either within that same gene or within other genes. This is happening sequentially, so the patient keeps receiving negative results, and then additional tests are ordered and the merry-go-round can continue for years. It cost families financially and emotionally. Delaying the time to diagnosis can also close the effective treatment window in cases where early treatment is important for a good prognosis.

Ordering a single whole-genome sequencing (WGS) test right off the bat replaces almost all of those long, cumbersome, and costly processes. It all but eliminates having to endure multiple genetic tests because a patient needs only one sample and one turnaround time for the greatest chance to arrive at the correct diagnosis. More importantly, if the test results were negative and then a new gene associated with the patients disease is reported the next day, and that patient has a variant in that gene, a clinician can make that connection by reanalyzing the data rather than by bringing the patient back in for a new sample. In that way, genomic testing has really revolutionized the entire genetic testing industry by providing a comprehensive analysis with the shortest time to diagnosis.

Whole-genome sequencing does not require the mechanical step of isolating genes first. It enables the identification of different types of variants that labs do not typically see when one isolates genes. It also enables the use of sophisticated algorithms applied via software to allow for the ranking of variants in a way that pulls variants that are known to cause the disease to the top of the list for examination. Variants can also be ranked by looking at the severity of the effect of the variant on genes that most closely match the patients clinical symptoms. Those results are parsed based on the known inheritance patterns of these genes. Patients can be looked at through both of those lenses at the same timethe severity of the changes that are identified, and the changes that match with the clinical symptoms of the patient.

Whole-genome testing will soon become the first line of defense, rather than a last resort for families or individuals seeking clarity on genetic diseases because of its ability to incorporate sophisticated bioinformatics and data interpretation. It is a faster route for the proper diagnosis and treatment for both early-onset diseases like epilepsy and intellectual disabilities, as well as late-onset disorders like ataxia and ALS. It can be used to diagnose almost any genetic disorder spanning such areas as neurology, endocrinology, nephrology, hearing and vision loss, blood disorders like thalassemia, muscular dystrophy, etc. While insurance reimbursement can be challenging today, the insurance payers will come around, as they have always done in the past, because this test saves time, money, and supports better outcomes for patients.

About Christine Stanley, Ph.D.

Christine Stanley, Ph.D., is the Chief Director of Clinical Genomics for Variantyx, a provider of highly specialized genetic testing to clinicians and their patients. Christine is responsible for overseeing clinical genomic interpretations and regulatory compliance for the clinical laboratory.

See original here:
Eliminating the Long, Cumbersome and Costly Diagnosis of Genetic Diseases - HIT Consultant

Predictive Genetic Testing and Consumer/Wellness Genomics Market: Snapshot

Genetic testing comprises examination of ones DNA. The term DNA refers to the chemical database that is responsible for conveying the instructions for functions that need to be performed by the body. Genetic testing is capable of revealing changes or mutations in the genes of living beings, which might result in any kind of disease or illness in the body.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1274

Predictive genetic testingrefers to the utilization of genetic testing methods in an asymptomatic individual to make a prediction about risk of contacting particular disease in future. These tests are regarded as representation of emerging class of medical tests, which differ in fundamental ways from the usual diagnostic tests.

The global predictive genetic testing and consumer/wellness genomics marketis likely to gather momentum owing to the benefits offered by predictive genetic testing.

The benefits of predictive genetic testing are

The global predictive genetic testing and consumer/wellness genomics marketis influenced by reducing cost of genetic sequencing and technological advancement in the field of genetics. North America is expected to emerge as a prominent region for the global predictive genetic testing and consumer/wellness genomics market in years to come due to high adoption rates of latest technologies in all fields.

Over centauries human DNA has undergone tremendous alteration due to evolutionary and lifestyle changes. They have led to both, advantages and disadvantages over the years. Some have given the mankind a deserving edge over other creatures while the others have led to disorders and diseases. Predictive genetic testing and consumer/wellness genomics market thrives on the growing demand for understanding the lineage of a certain gene pool to identify disorders that could manifest in the later or early stage of a human life. The surging demand for understanding the family history or studying the nature of certain diseases has given the global market for predictive genetic testing and consumer/wellness genomics market adequate fodder for growth in the past few years.

This new class of medical tests are aimed at reducing the risk of morbidity and mortality amongst consumers. The thorough surveillance and screening of a certain gene pool can allow an individual to avoid conditions that disrupt normal existence through preventive measures. The clinical utility of these tests remains unassessed. Therefore, increasing research and development by pharmaceutical companies to develop new drugs by understanding diseases and disorders is expected to favor market growth.

Unlike conventional diagnostic testing, predictive genetic testing identifies the risk associated with potential conditions. In certain cases it is also capable of stating when the disease may appear and the how severe will it be. Thus, this form of testing is expected to allow consumers to take up wellness measurements well in time to lead a life of normalcy, characterized by good health.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1274<ype=S

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Overview

Predictive genetic testing are used to identify gene mutations pertaining to the disorders that surface at a considerably later stage in life after birth. These tests are particularly beneficial for people from a family with a history of genetic disorder, although they themselves show no symptoms of the disorder at the time of testing. Genetic testing promises to revolutionize the healthcare sector, providing crucial diagnostic details related to diverse verticals such as heart disease, autism, and cancer. As the healthcare sector touches new peaks, the global predictive genetic testing and consumer/wellness genomics market is projected to expand at a healthy growth rate during the forecast period of 2017 to 2025.

This report on the global market for predictive genetic testing and consumer/wellness genomics analyzes all the important factors that may influence the demand in the near future and forecasts the condition of the market until 2025. It has been created using proven research methodologies such as SWOT analysis and Porters five forces. One of the key aspect of the report is the section on company profiles, wherein several leading players have been estimated for their market share and analyzed for their geographical presence, product portfolio, and recent strategic developments such as mergers, acquisitions, and collaborations.

The global predictive genetic testing and consumer/wellness genomics market, on the basis of test type, can be segmented into predictive testing, consumer genomics, and wellness genetics. The segment of predictive testing can be sub-segmented into genetic susceptibility test, predictive diagnostics, and population screening programs, whereas the segment of wellness genetics can be further divided into nutria genetics, skin and metabolism genetics, and others.

By application, the market can be segmented into breast and ovarian cancer screening, cardiovascular screening, diabetic screening and monitoring, colon cancer screening, Parkinsons or Alzheimers disease, urologic screening or prostate cancer screening, orthopedic and musculoskeletal screening, and other cancer screening. Geographically, the report studies the opportunities available in regions such as Asia Pacific, Europe, North America, and the Middle East and Africa.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Trends and Opportunities

Increasing number of novel partnership models, rapidly decreasing cost of genetic sequencing, and introduction of fragmented point-solutions across the genomics value chain as well as technological advancements in cloud computing and data integration are some of the key factors driving the market. On the other hand, the absence of well-defined regulatory framework, low adoption rate, and ethical concerns regarding the implementation, are expected to hinder the growth rate during the forecast period. Each of these factors have been analyzed in the report and their respective impacts have been anticipated.

Currently, the segment of predictive genetic cardiovascular screening accounts for the maximum demand, and increased investments in the field is expected to maintain it as most lucrative segment. On the other hand, more than 70 companies are currently engaged in nutrigenomics, which is expected to further expand the market.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Regional Outlook

Owing to robust healthcare infrastructure, prevalence of cardiovascular diseases, and high adoptability rate of new technology makes North America the most lucrative region, with most of the demand coming from the country of the U.S. and Canada. Several U.S. companies hold patents, which further extends the outreach of the market in the region of North America.

Companies mentioned in the research report

23andMe, Inc, BGI, Genesis Genetics, Illumina, Inc, Myriad Genetics, Inc, Pathway Genomics, Color Genomics Inc., and ARUP Laboratories are some of the key companies currently operating in global predictive genetic testing and consumer/wellness genomics market. Various forms of strategic partnerships with operating company and smaller vendors with novel ideas helps these leading players maintain their position in the market.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1274

More here:
Predictive Genetic Testing and Consumer/Wellness Genomics Market Analysis of Key Players 2025 - Cole of Duty

Molecular diagnostics market is projected to record significant gains over the forthcoming timeframe. Molecular diagnostics is one of the most transformative and dynamic areas of diagnostics, leading to various advancements in research and treatment which are revolutionizing healthcare throughout a wide array of medical conditions and diseases.

The term molecular diagnostics is a class of diagnostic tests that evaluate health of a person literally at a molecular level, measuring and detecting specific genetic sequences in RNA or DNA or the proteins they express.

Recent advances in molecular diagnostics are starting to shift from basic research to clinical reality. Some of the popular as well as cost-efficient diagnostic tests in medicine are based on quantification of a particular protein and are often used in hospitals globally.

Request sample copy of this report @ https://www.decresearch.com/request-sample/detail/434

Patients as well as families generally rely on molecular diagnoses for disease prognosis, family planning and health-care management, and they get benefits when an answer is found for the afflicting condition.

Based on the application landscape, the market is segmented into oncology testing, blood screening, genetic testing, and infectious disease. Among these, the genetic testing segment is projected to record a CAGR of around 11% between 2019 to 2020 owing to the increasing advancements in diagnostic tools enabling higher sensitivity and specificity.

Furthermore, genetic testing has grown from a niche field for rare disorders to a wide scope of applications for personal use and complex disease. Applications of clinical genetic testing range from medical disciplines, which includes carrier and diagnostic testing for inherited disorders; pharmacogenetic testing to guide individual drug selection, dosage and response; to screening of newborn for highly penetrant disorders; and pre-symptomatic and predictive testing for adult-onset and complex disorders.

Make Inquiry about this report @ https://www.decresearch.com/inquiry-before-buying/434

With respect to technology, the market is bifurcated into sequencing, isothermal amplification, PCR, chips & microarrays, in situ hybridization, mass spectrometry, and others. Among these, the in situ hybridization (ISH) segment is slated to record a market valuation of more than $3 billion by 2026, owing to the technological advancements that are allowing low cost gene mapping and diagnostics.

ISH is a technique allowing localization of a particular segment of nucleic acid within a histologic section. The fundamental basis of ISH is that nucleic acids if preserved effectively within a histologic specimen, could be discovered through the application of a corresponding strand of nucleic acid to which a reporter molecule is generally attached. The technique is specifically useful in neuroscience.

Other applications of ISH are microbiology, pathology, developmental biology, karyotyping, and phylogenetic analysis.

From a regional frame of reference, Latin America molecular diagnostics market is expected to reach a valuation of more than $1 billion by 2026, which is attributable to the rising awareness about cost-effective molecular diagnostics options among general population.

Molecular diagnostics has become an important part of disease management and therapy, used in applications areas like drug regimen selection, detection of predisposition to disease, patient stratification, toxicity avoidance, and therapeutic monitoring. This growing integrality of the industry is poised to help it grow significantly in coming years.

Read more here:
Molecular Diagnostics Market Detailed Analysis of Current Industry Figures with Forecasts Growth By 2025 - 3rd Watch News

People under 28 or over 30 in Madison, Morgan, Marshall, Jackson and Limestone counties can get reduced pricing on tests.

HUNTSVILLE, Ala. The HudsonAlpha Institute for Biotechnology is offering cancer genetic risk testing to all adults in Madison, Morgan, Marshall, Jackson and Limestone counties.

The test is free for people ages 28-30 and available at a reduced cost to others.

HudsonAlpha says that they have reached capacity for the free-for-all-adults testing program.

According to HudsonAlpha, the free test offered by Kailos Genetics screens for the well-known BRCA1 and BRCA2 genes, as well as several dozen other genes linked to breast, ovarian, colon, prostate, pancreatic, and other cancers.

The testing is offered through the Information is Power initiative, established in 2015 for people interested in learning more about their cancer risk.

If you want to learn more about genetic testing for cancer risk, HudsonAlpha, the Princess Theatre, and Decatur Morgan Women's Healthcare are holding a free virtual event July 15 at noon. Cancer researcher, Sara Cooper, PhD, and genetic counselor, Veronica Greve, will discuss the latest in cancer research and genetic testing.

You're also eligible to win a free test, regardless of age, a free test, if you register to attend the virtual event on July 15.

To join the virtual event, register here.

To order a test for yourself or someone else, click here.

Read the original:
Free cancer genetic risk testing available to adults 28-30 in five counties - WZDX

Global Predictive Genetic Testing Market 2020-2025 is one of the most comprehensive and important additions to Adroit Market Research archive of market research studies. It offers detailed research and analysis of key aspects of the global market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Predictive Genetic Testing market. The report also analyzes factors such as drivers, restraints, opportunities, and trends affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides particulars of the competitive landscape for market leaders.

Get sample copy of Predictive Genetic Testing Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/1276

The analysis is likely to create in-depth analysis predicated on preceding questions and comprehensive research regarding the evolution setting, market dimensions, development tendency, performance status and future development tendency of Predictive Genetic Testing market on based on saying current position 2020 therefore as to create complete organization and decision on your contest situation and development tendency of global Predictive Genetic Testing market and assist brands and investment company to grasp the growth span of the market.

Top Leading Key Players are:

Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/predictive-genetic-testing-market

Predictive Genetic Testing market is split by Type and by Application. For the period 2020-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets. Predictive Genetic Testing market competitive landscape provides details by vendors, including company overview, company total revenue, market potential, global presence, sales and revenue generated, market share, price, production sites and facilities, SWOT analysis.

Predictive Genetic Testing market study further highlights the segmentation of the Predictive Genetic Testing industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Predictive Genetic Testing market report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Predictive Genetic Testing market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Predictive Genetic Testing market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1276

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

More:
Predictive Genetic Testing Market: Expected to Demand Product Scope, Market Summary, Prospects and Driving Force 2025 - Jewish Life News

New Jersey, United States,- The latest research study on Prenatal and New-born Genetic Testing Market Added by Verified Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Prenatal and New-born Genetic Testing market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

Global Prenatal and Newborn Genetic Testing Market was valued at USD 7.07 Billion in 2019 and is projected to reach USD 15.85 Billion by 2027, growing at a CAGR of 10.6% from 2020 to 2027.

Download Sample Copy of Prenatal and New-born Genetic Testing Market Report Study 2020-2027 @ https://www.verifiedmarketresearch.com/download-sample/?rid=38619&utm_source=COD&utm_medium=002

The research report on the Prenatal and New-born Genetic Testing market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Major Players Covered in this Report are:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Prenatal and New-born Genetic Testing market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

The scope of the Report:

The report segments the global Prenatal and New-born Genetic Testing market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritty of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also addresses political scenarios that are expected to impact the market in both small and big ways. The report on the global Prenatal and New-born Genetic Testing market examines changing regulatory scenarios to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Discount on Prenatal and New-born Genetic Testing Market Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=38619&utm_source=COD&utm_medium=002

As per the regional scope of the Prenatal and New-born Genetic Testing market:

Highlights of the report:

Key Questions Answered in the report:

Learn More about this report @ https://www.verifiedmarketresearch.com/product/prenatal-and-newborn-genetic-testing-market/?utm_source=COD&utm_medium=002

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Hardware Security Modules Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Physical Security Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Wearable Electronics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Microgrid Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Scintillator Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Original post:
Prenatal and New-born Genetic Testing Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 - Cole of Duty

Learn details of the Preimplantation Genetic Testing Market: Statistics, Facts And Figures, Growth Overview, Size, Major Players, Industry Outlook And Regional Analysis, Swot Analysis And Forecast To 2029. Extensive Study on Impact of the novel coronavirus (COVID 19) pandemic on the preimplantation genetic testing market based on Current Analysis of Potential Growth Challenges and Future Developments till 2029.

The Preimplantation Genetic Testing report encompasses a careful analysis of a small and economic science issue that is influencing the expansion of the market. The Preimplantation Genetic Testing market has cardinal frameworks that embody market outlook, Preimplantation Genetic Testing current methods, institution, size, revenue and latest trends of Preimplantation Genetic Testing market from 2020-2029.The Influential Players Covered In This Report Are: Illumina, Thermo Fisher, Agilent Technologies, Perkinelmer, Coopersurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Gen.

Download the PDF Sample To Understand The CORONA Virus/COVID19 Impact On Preimplantation Genetic Testing Market :https://market.us/report/preimplantation-genetic-testing-market/request-sample/

**Note:Our Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC,DetailedList of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology**

The report conjointly provides a summary of producing knowledge that includes: size, revenue(USD), statistics, development, worth and market value. The analysis for Preimplantation Genetic Testing analyzes current and future prospects to grasp the steadiness of the market. the worldwide Preimplantation Genetic Testing market have comprehensive prospect that covers the assorted facet of preimplantation genetic testing market. The Preimplantation Genetic Testing is organized by existing fantastic and current market state of affairs.

The key makers of Preimplantation Genetic Testing enclosed within the reports are:

Perkinelmer, Rubicon Genomics, Scigene, Illumina, Gen, Agilent Technologies, Oxford Gene Technology, Beijing Genomics Institute, Abbott Laboratories, Good Start Genetics, Combimatrix, Yikon Genomics, Thermo Fisher, Natera, Coopersurgical and Invicta Genetics

Market Segment By Types:

Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening

Market Segment By Applications :

Hospitals, Maternity Centers & Fertility Clinics, Research Laboratories & Academic Institutes, and Service Providers and Diagnostic Labs

Key Regions split during this report:

North America (the USA, North American country and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (India, China, Japan, Korea and Southeast Asia)

South America ( Columbia, Brazil, Argentinaetc.)

The Middle East and continent (Saudi Arabian Peninsula, UAE, Egypt, African country and South Africa)

To Purchase The Report Click Here:https://market.us/purchase-report/?report_id=12405

Key Reasons to shop for the report:

-To induce a discriminating survey of preimplantation genetic testing market and have the numerous that means of the worldwide Preimplantation Genetic Testing market and its comprehensive landscape.

-Assess international preimplantation genetic testing market production processes, major issues, and solutions to decrease the expansion risk.

-To know the foremost vast drives and restraint forces in Preimplantation Genetic Testing Market and its collision within the international market.

-To own the summary regarding preimplantation genetic testing market methods that are being applied by leading various industries.

-To know the excellent outlook and prospects for preimplantation genetic testing market.

-Save and decrease time carrying out entry-level research by identifying the growth, size, major players and segments in the global preimplantation genetic testing market

-Highlights key business significances and priorities in order to support companies to rearrange their business strategies.

-The key findings and proposals highlight crucial progressive industry trends in the Preimplantation Genetic Testing Market, thereby allowing players to develop effective long-term strategies.

-Develop or modify business development plans by using considerable growth offering developed and emerging markets.

-Examine in-depth global preimplantation genetic testing market trends and outlook coupled with the factors driving the market, as well as those hindering it.

-Improve the decision-making process by understanding the strategies that support commercial credit with respect to products, segmentation and industry verticals.

Get in-depth analysis of the COVID-19 impact on the Preimplantation Genetic Testing Market :https://market.us/report/preimplantation-genetic-testing-market//#inquiry

Lastly, the preimplantation genetic testing report offers market size and estimates for the period from 2019 to 2028, keeping in mind the above-mentioned factors. This report will be helpful for preimplantation genetic testing vendors, system integrators, and related business partners to understand key investment areas and define their strategies. In addition, this analysis study covers intensive research of various market sections based on applications, study across completely different geographies and products.

Why Go For Market.us Research?

Market.US specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons. We offer tactical and strategic support, which enables our esteemed clients to make well-informed business decisions and chart out future plans and attain success every single time. Besides analysis and scenarios, we provide insights into global, regional, and country-level information and data, to ensure nothing remains hidden in any target market. Our team of tried and tested individuals continues to break barriers in the field of market research as we forge forward with a new and ever-expanding focus on emerging markets.

Get in Touch with Us :

Mr. Benni Johnson

Market.us (Powered By Prudour Pvt. Ltd.)

Send Email:inquiry@market.us

Address:420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Tel:+1 718 618 4351

Website:https://market.us

See more here:
New Research on Preimplantation Genetic Testing Market by Trending Key players-Illumina, Thermo Fisher, Agilent Technologies - Galus Australis

An Owensboro woman recently discovered a big sister she never knew she had living in Germany. Randi Caldwell and Crimson Smith are meeting for the first time later this year after finding each other through genetic testing.

Caldwells mother died when she was very young, and now as a mother herself, she wanted to learn more about her history and heritage for her own daughter.

So Caldwell purchased a 23andMe DNA kit to learn more. Her initial results were nothing unexpected, but this spring she received the surprise of a lifetime a message from a woman matched with her as a half-sister.

Caldwell said as she was growing up she lost her family one at a time. Her mother died when she was 4 and the man she thought was her father died in 2010, and she was then raised by his parents. They passed away when she was a teenager, and Caldwell bounced around from state to state for a while.

I learned during this time that my dad wasnt my real father, but because my mother was deceased no one had any idea of who he may be, other than she once mentioned he lived in Georgia, she said.

In 2019 at 30 years old and as a single mom, Caldwell decided to find out more.

I wanted to see if I could learn anything about my family by doing a DNA test, she said. This was my only option because no family members were left. I got my results and lots of second- and third-cousins, but none that I recognized. I did learn a lot about my medical history, which I was happy about.

In March of this year, Calwell woke up to a message on the 23andMe app from a female in Germany.

She said that she had taken the test and it claimed we were half-sisters, Caldwell said. She asked me if there was any way it could be true.

Caldwell said it took her a few moments to gather her thoughts but she messaged back and then waited.

I did some digging and found her on social media, Caldwell said. When I looked at her photos I was shocked at how we looked so much alike.

Smith is 16 years older than Caldwell, and together they figured out that their shared father met Caldwells mother while on vacation.

Caldwell was thrilled to find out the identity of her birth father, though disappointed to learn he died before the age of 50 from heart disease. However, she was glad to learn about this important health history for herself and her daughter.

Caldwell and Smith message constantly now that they have connected. Smith is based in Germany with the military and is hoping to visit the U.S. this summer to meet in-person for the first time.

Its strange to see pictures of an entire family that look just like me, Caldwell said. Im excited for the future and what it holds.

Go here to see the original:
DNA testing connects Owensboro woman to half-sister in Germany - The Owensboro Times

New Jersey, United States,- The latest research study on Preimplantation Genetic Testing Market Added by Verified Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Preimplantation Genetic Testing market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

Global Preimplantation Genetic Testing Market was valued at USD 306.16 million in 2016 and is projected to reach USD 701.49 million by 2025, growing at a CAGR of 9.65% from 2017 to 2025.

Download Sample Copy of Preimplantation Genetic Testing Market Report Study 2020-2027 @ https://www.verifiedmarketresearch.com/download-sample/?rid=24037&utm_source=APS&utm_medium=007

The research report on the Preimplantation Genetic Testing market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Major Players Covered in this Report are:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Preimplantation Genetic Testing market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

The scope of the Report:

The report segments the global Preimplantation Genetic Testing market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritty of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also addresses political scenarios that are expected to impact the market in both small and big ways. The report on the global Preimplantation Genetic Testing market examines changing regulatory scenarios to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Discount on Preimplantation Genetic Testing Market Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24037&utm_source=APS&utm_medium=007

As per the regional scope of the Preimplantation Genetic Testing market:

Highlights of the report:

Key Questions Answered in the report:

Learn More about this report @ https://www.verifiedmarketresearch.com/product/Preimplantation-Genetic-Testing-Market/?utm_source=APS&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Cellular Health Screening-Health Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Preimplantation Genetic Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Cell Based Assays Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Protein Expression Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Analytical Standards Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Originally posted here:
Preimplantation Genetic Testing Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 - Apsters News